Frail elderly patients with relapsed-refractory multiple myeloma: efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide

被引：12
|
作者：
Mele, Giuseppe [1 ]
Giannotta, Angela
Pinna, Salvatore
Loseto, Giacomo
Coppi, Maria Rosaria
Brocca, Claudio Maurizio
Melpignano, Angela
Quarta, Giovanni
机构：
[1] Antonio Perrino Hosp, Clin Div Hematol, I-72100 Brindisi, Italy
来源：
LEUKEMIA & LYMPHOMA | 2010年 / 51卷 / 05期
关键词：
PREDNISONE PLUS THALIDOMIDE; MELPHALAN;
D O I：
10.3109/10428191003695660
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：937 / 940
页数：4
相关论文
共 50 条
  • [31] Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
    Offidani, M.
    Corvatta, L.
    Maracci, L.
    Liberati, A. M.
    Ballanti, S.
    Attolico, I.
    Caraffa, P.
    Alesiani, F.
    di Toritto, T. Caravita
    Gentili, S.
    Tosi, P.
    Brunori, M.
    Derudas, D.
    Ledda, A.
    Gozzetti, A.
    Cellini, C.
    Malerba, L.
    Mele, A.
    Andriani, A.
    Galimberti, S.
    Mondello, P.
    Pulini, S.
    Coppetelli, U.
    Fraticelli, P.
    Olivieri, A.
    Leoni, P.
    BLOOD CANCER JOURNAL, 2013, 3 : e162 - e162
  • [32] BORTEZOMIB, LOW DOSE INTRAVENOUS MELPHALAN AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED MULTIPLE MYELOMA
    Popat, R.
    Oakervee, H.
    Williams, C.
    Cook, M.
    Craddock, C.
    Basu, S.
    Singer, C.
    Odeh, L.
    Foot, N.
    Joel, S.
    Hallam, S.
    Harding, S.
    Mead, G.
    Cavenagh, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 365 - 366
  • [33] Bortezomib, low dose iv melphalan and dexamethasone for patients with relapsed multiple myeloma
    Popat, R.
    Williams, C.
    Cook, M.
    Craddock, C.
    Basu, S.
    Singer, C.
    Odeh, L.
    Foot, N.
    Joel, S.
    Hallam, S.
    Oakervee, H.
    Cavenagh, J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 : 120 - 120
  • [34] A Phase 1/2 Trial of Low-Dose Continuous Azacitidine in Combination with Lenalidomide and Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma
    Khouri, Jack
    Faiman, Beth
    Wei, Wei
    Grabowski, Dale
    Samaras, Christy Joy
    Mahfouz, Reda
    Lazarus, Hillard
    Dean, Robert
    Malek, Eshan
    Reed, Janice
    Karam, Mary Ann
    Hamilton, Kimberly
    Rosko, Nathaniel
    Fada, Sherry
    Kalaycio, Matt
    Liu, Hien
    Saunthararajah, Yogen
    Chew, Yap
    Valent, Jason
    Reu, Frederic
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E262 - E263
  • [35] Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
    Song Mu
    Yoshiaki Kuroda
    Hirohiko Shibayama
    Masayuki Hino
    Takeshi Tajima
    Claudia Corrado
    Rong Lin
    Edward Waldron
    Florence Binlich
    Kenshi Suzuki
    European Journal of Clinical Pharmacology, 2016, 72 : 153 - 161
  • [36] Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
    Mu, Song
    Kuroda, Yoshiaki
    Shibayama, Hirohiko
    Hino, Masayuki
    Tajima, Takeshi
    Corrado, Claudia
    Lin, Rong
    Waldron, Edward
    Binlich, Florence
    Suzuki, Kenshi
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (02) : 153 - 161
  • [37] Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma RRMM)
    Kumar, Shaji
    Grzasko, Norbert
    Delimpasi, Sossana
    Jedrzejczak, Wieslaw
    Grosicki, Sebastian
    Kyrtsonis, Marie Christine
    Spencer, Andrew
    Gupta, Neeraj
    Teng, Zhaoyang
    Byrne, Catriona
    Labotka, Richard
    Dimopoulos, Meletios Athanasios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E131 - E131
  • [38] Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
    Kumar, Shaji
    Grzasko, Norbert
    Delimpasi, Sosana
    Jedrzejczak, Wieslaw W.
    Grosicki, Sebastian
    Kyrtsonis, Marie-Christine
    Spencer, Andrew
    Gupta, Neeraj
    Teng, Zhaoyang
    Byrne, Catriona
    Labotka, Richard
    Dimopoulos, Meletios A.
    BLOOD, 2016, 128 (22)
  • [39] A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
    Chari, Ajai
    Cho, Hearn Jay
    Parekh, Samir
    Lau, Kenneth
    Morgan, Gillian
    Catamero, Donna
    Cortes, Melissa
    Curtis, Meredith
    Escalon, Juliet
    Florendo, Erika
    Verina, Daniel
    Stevens, Nadege
    Chan, Elaine
    Garcia, Katarzyna
    La, Lisa
    Shields, Marisa
    Strumolo, Gina
    Jagannath, Sundar
    BLOOD, 2016, 128 (22)
  • [40] Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma
    Murakami, Hirokazu
    Handa, Hiroshi
    Abe, Masahiro
    Iida, Sinsuke
    Ishii, Akihiro
    Ishikawa, Takayuki
    Ishida, Tadao
    Oota, Masatsugu
    Ozaki, Shuji
    Kosaka, Masaaki
    Sakai, Akira
    Sawamura, Morio
    Shimazaki, Chihiro
    Shimizu, Kazuyuki
    Takagi, Toshiyuki
    Hata, Hiroyuki
    Fukuhara, Takashi
    Fujii, Hiroshi
    Miyata, Akira
    Wakayama, Toshio
    Takatsuki, Kiyoshi
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2007, 79 (03) : 234 - 239
12345